We apply high-throughput transcriptomics to match drugs to a disease based not just on a single target, but the biological network as a whole. Arpeggio embraces the complexity of biology by defining a drug's impact on hundreds of thousands of RNA molecules at once. This allows us to accurately predict whether a molecule could be an effective therapy. By scaling our transcriptomics platform, we're gearing up to accelerate the pace and efficiency of drug discovery and find new therapies for challenging diseases like drug-resistant cancer.

Every cell in our body contains the same DNA sequence, yet heart cells are very different from liver cells. This is due to thousands of differences in how these cells generate (or transcribe) RNA. With our growing RNA dataset, Arpeggio is learning connections between RNA expression, cell type, and disease. Many common diseases such as cancer and neurodegeneration are driven not just by dysfunction of a single gene but by the misregulation of hundreds or thousands of RNAs. At Arpeggio, we compare healthy and diseased cell states to identify RNA signatures that define disease. By identifying these RNAs we search for drugs that specifically reverse disease signatures. Arpeggio utilizes a unique technology called nascent RNA sequencing to measure RNAs directly affected by a compound treatment. This allows us to identify the primary effect of a drug on a cell and very quickly hone in on its mechanism. With new advances in next-generation sequencing and robotics, we're scaling our nascent RNA sequencing platform to test tens of thousands of compounds at a time. Arpeggio has built the world's largest database of nascent RNA sequences. For the first time, we are linking compound Structure-Activity Relationships with RNA fingerprints. Our database guides drug development by enabling predictions for whether a molecule will be toxic or impactful for a patient.